Abstract LB 212: Therapeutic efficacy of the paradox breaking panRAF and SRC drug CCT3833/BAL3833 in KRAS driven cancer models
KRAS is mutated in ~80% of pancreatic ductal adenocarcinoma (PDAC) ~35% of colorectal cancer (CRC) and ~20% of non small cell lung cancer (NSCLC) KRAS remains an intractable drug target and targeting the downstream pathway component is ineffective because feedback mechanisms or parallel pathways provide alternative routes to cell proliferation and/or survival. Here we show that a new panRAF/SRC inhibitor, CCT3833, is active in KRAS mutant PDAC, CRC and NSCLC. We demonstrate that CCT3833 inhibits tumor growth in several KRAS driven cancers via inhibition of RAF and SRC, eliciting therapeutic efficacy at well tolerated doses in mouse models of human cancer. CCT3833 has already entered clinical trials (NCT02437227) for BRAF mutant and BRAF inhibitor resistant melanomas and these new data show that it is also effective in KRAS mutant cancers, potentially providing a new therapeutic option for these patients. Citation Format: Grazia Saturno, Filipa Lopes, Maria Romina Girotti, Ion Niculescu Duvaz, Dan Niculescu Duvaz, Alfonso Zambon, Lawrence Davies, Louise Johnson, Natasha Preece, Amaya Viros, Malin Pedersen, Robert McLeary, Ruth Knight, Rebecca Lee, Denys Holovanchuk, Paul Lorigan, Nathalie Dhomen, Richard Marais, Caroline Springer. Therapeutic efficacy of the paradox breaking panRAF and SRC drug CCT3833/BAL3833 in KRAS driven cancer models. [abstract] In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16 20; New Orleans, LA. Philadelphia (PA) AACR; Cancer Res 2016;76(14 Suppl):Abstract nr LB 212.